Therapeutic Potential and Preclinical Trials of Mesenchymal Stem Cells and Their EVs for Atherosclerosis and Clinical Trials of MSC-Derived EVs for Cardiovascular Diseases

Atherosclerosis is a progressive disease driven by dyslipidemia, endothelial dysfunction, inflammation, oxidative stress, and vascular cell dysfunction. Extracellular vesicles (EVs) contribute to atherosclerotic pathogenesis by regulating intercellular communication, inflammatory responses, endothelial function, and vascular smooth muscle cell phenotypic switching. Premature mortality of the population and consequences in the form of cardiovascular diseases as well as early disability necessitate the search for new approaches to the treatment of atherosclerosis. Mesenchymal stem cells (MSCs) possess immunosuppressive, regenerative and atheroprotective effects, and MSCs that were preconditioned with cytokines and hypoxia are believed to have a more enhanced effect. Preclinical studies in animal models of atherosclerosis demonstrate that MSC-derived EVs can reduce lesion burden and inflammation in the early phase of atherosclerosis. However, small group sizes, heterogeneous methods of isolation of EVs and dosing, and the lack of tests in advanced lesions limit these findings. It is becoming evident that attempts are being made to utilize EVs for the treatment of cardiovascular diseases. However, the clinical studies reviewed here do not report specific results regarding the use of such EVs, which complicates a deeper understanding of this subject. It can be hypothesized that, perhaps due to a lack of sufficient clinical research, the use of EVs for human atherosclerosis has not yet been explored. Furthermore, several critical factors remain to be considered, including: the source of the MSCs from which EVs are isolated; the genetic profile and the presence of chronic conditions in the donor; the culture system of MSCs; the culture media (specifically the absence of components of animal origin); the parameters of the EVs’ isolation method; and the route of administration of the EVs into the body, as well as their subsequent elimination. In this review, we considered the therapeutic perspective of MSCs and MSC-derived EVs, compiled the preclinical and clinical trials in accordance with disease category and mentioned the aspects of using EVs before clinical translation.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-11-16
DOI
https://doi.org/10.3390/jcm15228965
Primary Topic
Extracellular vesicles in disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Therapeutic Potential and Preclinical Trials of Mesenchymal Stem Cells and Their EVs for Atherosclerosis and Clinical Trials of MSC-Derived EVs for Cardiovascular Diseases

Madina Zhunussova, Meruyert Imanbekova, Vyacheslav B. Ogay, Aliya Sekenova et al.
Journal of Clinical Medicine
Extracellular vesicles in disease
article

Therapeutic Potential and Preclinical Trials of Mesenchymal Stem Cells and Their EVs for Atherosclerosis and Clinical Trials of MSC-Derived EVs for Cardiovascular Diseases

Madina Zhunussova, Meruyert Imanbekova, Vyacheslav B. Ogay, Aliya Sekenova, Miras Shakhatbayev
article en

Abstract

Atherosclerosis is a progressive disease driven by dyslipidemia, endothelial dysfunction, inflammation, oxidative stress, and vascular cell dysfunction. Extracellular vesicles (EVs) contribute to atherosclerotic pathogenesis by regulating intercellular communication, inflammatory responses, endothelial function, and vascular smooth muscle cell phenotypic switching. Premature mortality of the population and consequences in the form of cardiovascular diseases as well as early disability necessitate the search for new approaches to the treatment of atherosclerosis. Mesenchymal stem cells (MSCs) possess immunosuppressive, regenerative and atheroprotective effects, and MSCs that were preconditioned with cytokines and hypoxia are believed to have a more enhanced effect. Preclinical studies in animal models of atherosclerosis demonstrate that MSC-derived EVs can reduce lesion burden and inflammation in the early phase of atherosclerosis. However, small group sizes, heterogeneous methods of isolation of EVs and dosing, and the lack of tests in advanced lesions limit these findings. It is becoming evident that attempts are being made to utilize EVs for the treatment of cardiovascular diseases. However, the clinical studies reviewed here do not report specific results regarding the use of such EVs, which complicates a deeper understanding of this subject. It can be hypothesized that, perhaps due to a lack of sufficient clinical research, the use of EVs for human atherosclerosis has not yet been explored. Furthermore, several critical factors remain to be considered, including: the source of the MSCs from which EVs are isolated; the genetic profile and the presence of chronic conditions in the donor; the culture system of MSCs; the culture media (specifically the absence of components of animal origin); the parameters of the EVs’ isolation method; and the route of administration of the EVs into the body, as well as their subsequent elimination. In this review, we considered the therapeutic perspective of MSCs and MSC-derived EVs, compiled the preclinical and clinical trials in accordance with disease category and mentioned the aspects of using EVs before clinical translation.

Journal of Clinical MedicineVol. 15(22)
National Center for Biotechnology (KZ)
Extracellular vesicles in disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon